Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$2.84 USD
+0.30 (11.81%)
Updated May 14, 2024 04:00 PM ET
After-Market: $2.75 -0.09 (-3.17%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
Cyclacel Pharmaceuticals, Inc. [CYCC]
Reports for Purchase
Showing records 61 - 75 ( 75 total )
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
CDK7 and CDK9 Inhibitors: A New Class of Drugs to Watch From AACR
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
There Is Value to the Remaining Clinical Pipeline; Maintain Buy and Lowering PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Our Thoughts on Valuation Ahead of Pivotal AML Data and the Lateral Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A THREE STAR A PATENTVEST IP GROWTH COMPANY - 2011 BEST AND BRIGHTEST PATENTVEST REPORTS
Provider: MDB CAPITAL GROUP LLC